728x90 wearable artificial pancreas1 이오플로우, EOFlow Issues Convertible Bonds Worth 35 Billion Korean Won EOFlow Issues Convertible Bonds Worth 35 Billion Korean Won...Raised Capital Will be Used on Clinical Trials, R&D and Investment in New Businesses ▶ EOFlow aims to develop clinical studies and R&D of wearable artificial pancreas (AP), develop R&D and investments in new wearable drug delivery solutions ▶ EOFlow secures mid- to long-term growth momentum based on the innovative EOPatch platform tec.. 2021. 1. 20. 이전 1 다음 320x100
